Eupraxia Pharmaceuticals Inc
EPRX7.050USD
+0.050+0.71%
交易中 （美东）报价延迟15分钟
356.72M总市值
亏损市盈率 TTM
关于 Eupraxia Pharmaceuticals Inc 公司
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
Eupraxia Pharmaceuticals Inc简介
公司代码EPRX
公司名称Eupraxia Pharmaceuticals Inc
上市日期Mar 09, 2021
CEOHelliwell (James A)
员工数量33
证券类型Ordinary Share
年结日Mar 09
公司地址201-2067 Cadboro Bay Rd.
城市VICTORIA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编V8R 5G4
电话12505903968
网址https://eupraxiapharma.com/home/default.aspx
公司代码EPRX
上市日期Mar 09, 2021
CEOHelliwell (James A)
Eupraxia Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.50%
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
16.39K
+17.70%
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
228.23K
+1.50%
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
16.39K
+17.70%
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月21日 周五
更新时间: 11月21日 周五
持股股东
股东类型
持股股东
持股股东
占比
Manchester Management Company, L.L.C.
10.98%
Beutel, Goodman & Company Ltd.
8.01%
Disbrow (Robert)
6.65%
Freedman (Joseph S)
4.09%
Vivo Capital, LLC
2.67%
其他
67.59%
持股股东
持股股东
占比
Manchester Management Company, L.L.C.
10.98%
Beutel, Goodman & Company Ltd.
8.01%
Disbrow (Robert)
6.65%
Freedman (Joseph S)
4.09%
Vivo Capital, LLC
2.67%
其他
67.59%
股东类型
持股股东
占比
Hedge Fund
18.91%
Individual Investor
17.49%
Investment Advisor
10.30%
Venture Capital
4.44%
Research Firm
2.77%
Investment Advisor/Hedge Fund
0.85%
其他
45.23%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
25
2.42M
4.29%
--
2025Q3
25
2.42M
4.29%
+50.65K
2025Q2
23
2.37M
6.13%
+179.23K
2025Q1
19
2.20M
5.41%
+276.41K
2024Q4
17
1.89M
5.38%
+22.30K
2024Q3
16
6.03M
9.48%
+71.78K
2024Q2
12
5.96M
4.63%
+4.51M
2024Q1
3
1.45M
6.20%
-759.20K
2023Q4
4
4.37M
8.10%
--
2023Q3
4
4.37M
9.24%
--
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Disbrow (Robert)
2.89M
5.72%
+2.89M
--
Sep 30, 2024
Freedman (Joseph S)
2.07M
4.1%
+561.53K
+37.16%
Sep 26, 2025
Montalbano (John S.)
1.28M
2.53%
+67.27K
+5.55%
Sep 24, 2025
Scotia Capital Inc.
1.29M
2.55%
-260.69K
-16.79%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Eupraxia Pharmaceuticals Inc的前五大股东是谁？
Eupraxia Pharmaceuticals Inc 的前五大股东如下：
Disbrow (Robert)持有股份：2.89M，占总股份比例：5.72%。
Freedman (Joseph S)持有股份：2.07M，占总股份比例：4.10%。
Montalbano (John S.)持有股份：1.28M，占总股份比例：2.53%。
Scotia Capital Inc.持有股份：1.29M，占总股份比例：2.55%。
Disbrow (Robert)持有股份：2.89M，占总股份比例：5.72%。
Freedman (Joseph S)持有股份：2.07M，占总股份比例：4.10%。
Montalbano (John S.)持有股份：1.28M，占总股份比例：2.53%。
Scotia Capital Inc.持有股份：1.29M，占总股份比例：2.55%。
Eupraxia Pharmaceuticals Inc的前三大股东类型是什么？
Eupraxia Pharmaceuticals Inc 的前三大股东类型分别是：
Manchester Management Company, L.L.C.
Beutel, Goodman & Company Ltd.
Disbrow (Robert)
Manchester Management Company, L.L.C.
Beutel, Goodman & Company Ltd.
Disbrow (Robert)
有多少机构持有Eupraxia Pharmaceuticals Inc(EPRX)的股份？
截至2025Q4，共有25家机构持有Eupraxia Pharmaceuticals Inc的股份，合计持有的股份价值约为2.42M，占公司总股份的4.29%。与2025Q3相比，机构持股有所增加，增幅为-0.00%。
哪个业务部门对Eupraxia Pharmaceuticals Inc的收入贡献最大？
在--，--业务部门对Eupraxia Pharmaceuticals Inc的收入贡献最大，创收--，占总收入的--%。
